SLC5A2 and chronic kidney disease: The renal protective role conferred by SGLT2 inhibitors is to reduce the decline in renal function (proven outcome in the CANVAS Program, DECLARE-TIMI 58 and EMPA-REG OUTCOME trials) or to stabilize and slow the progression of chronic kidney disease in previously diagnosed patients (EMPA-Kidney, DAPA-CKD) [87].